LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia

LAG3’s Enigmatic Mechanism of Action

(2021) Colin G. Graydon et al.   Frontiers in Immunology

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy

(2021) Yihang Qi et al.   Frontiers in Immunology

Mechanisms of Resistance to NK Cell Immunotherapy

(2020) Christian Sordo-Bahamonde et al.   Cancers

Progress of immune checkpoint LAG‑3 in immunotherapy (Review)

(2020) Chanchan Shan et al.   Oncology Letters

LAG-3: from molecular functions to clinical applications

(2020) Takumi Maruhashi et al.   Journal for ImmunoTherapy of Cancer

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm

(2020) Quentin Lecocq et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression

(2020) Ana P. Gonzalez-Rodriguez et al.   Journal of Clinical Medicine

Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells

(2019) Priscilla Do et al.   JOURNAL OF IMMUNOLOGY

PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression

(2019) Alberto Mussetti et al.   ANNALS OF HEMATOLOGY

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

(2019) Paola Dama et al.   Journal for ImmunoTherapy of Cancer

T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma

(2019) Fabienne Lucas et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming

(2019) Aimee Merino et al.   JOURNAL OF CLINICAL INVESTIGATION

NK Cells in the Treatment of Hematological Malignancies

(2019) Gonzalez-Rodriguez et al.   Journal of Clinical Medicine

LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer

(2019) Cinzia Solinas et al.   Cancers

Harnessing innate immunity in cancer therapy

(2019) Olivier Demaria et al.   NATURE

Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia

(2018) Wen-Ting Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer

(2018) Guoying Zhou et al.   OncoImmunology

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

(2018) Jun Wang et al.   CELL

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia

(2018) Mónica Villa-Álvarez et al.   Frontiers in Immunology

NK Cell-Based Immunotherapy in Cancer Metastasis

(2018) Seila Lorenzo-Herrero et al.   Cancers

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia

(2017) Mika Shapiro et al.   HAEMATOLOGICA

Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma

(2017) Zhi-Zhang Yang et al.   Oncotarget

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia

(2017) Mika Shapiro et al.   HAEMATOLOGICA

Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia

(2017) Mónica Villa-Álvarez et al.   OncoImmunology

NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors

(2017) Alexander W. MacFarlane et al.   OncoImmunology

shinyGEO: a web-based application for analyzing gene expression omnibus datasets

(2016) Jasmine Dumas et al.   BIOINFORMATICS

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

(2016) Emily M. McWilliams et al.   OncoImmunology

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease

(2014) Leticia Huergo-Zapico et al.   PLoS One

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

(2014) Andrea Acebes-Huerta et al.   Biomed Research International

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

(2012) J. C. Riches et al.   BLOOD

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia

(2008) Shanique Palmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

The immunodeficiency of chronic lymphocytic leukaemia

(2008) A. D. Hamblin et al.   BRITISH MEDICAL BULLETIN